Henry Schein enters exclusive distribution agreement with CytoChip to enhance access to POC hematology testing
Henry Schein, Inc. entered into a new exclusive distribution agreement with CytoChip Inc. for its flagship product, the CitoCBC system, a 510(k) cleared device. Available now to Henry Schein customers in the United States, this solution is the first cartridge-based Complete Blood Count (CBC) system to receive a CLIA waiver status from the U.S. Food and Drug Administration (FDA), a designation that helps expand access to accurate, lab-quality hematology testing at the point of care.
“We are pleased to join with CytoChip to provide the CitoCBC System to our customers, helping to bring essential lab testing out of the hospital and into the office, with results provided to the patient during their visit,” said Ty Ford, Vice President and General Manager of Sales for Henry Schein Medical.
The CitoCBC system offers:
- Fast results: Delivering full test results in eight minutes.
- Ease of use: Requiring minimal staff training.
- Small sample: Using blood collected in a venous draw tube to analyze 16 parameters of the blood cells, including all five types of white blood cells.
- Lab-quality accuracy: Miniaturizing advanced lab technology (fluorescent flow cytometry) onto a small “Chip,” CitoCBC provides the result accuracy expected from a central laboratory, but on a countertop device.
“Partnering with Henry Schein enables us to expand the reach of CitoCBC, assisting health care providers in places like physician offices, urgent care centers, and even pharmacies, to get immediate diagnostic data,” said Dr. Wendian Shi, CEO of CytoChip. “Together, we can help make diagnostic decisions more informed than ever before –improving patients’ access to care.”
Henry Schein’s exclusivity in the U.S. includes ambulatory care settings such as physician offices, urgent care centers, and more, as well as critical access hospitals with 25 patient beds or fewer. It does not include long-term care or acute care facilities.
For more product information, please visit https://www.henryschein.com/citocbc.
*The CitoCBC system is not indicated for use in diagnosing or monitoring of oncology patients, critically ill patients, or children under the age of 2 years.
